Last edition
News about " KMT2A Rearrangements in AML Trials"
New Invivoscribe Platform Targets KMT2A Rearrangements in AML Trials
Invivoscribe, a precision diagnostics company focused on measurable residual disease (MRD) testing, has expanded its oncology portfolio with the launch of the LeukoStrat KMT2A + MRD Assay and Software.
KMT2A Rearrangements In AML Trials | 06/02/2026 | By Darshana | 151
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members